Recent

% | $
Quotes you view appear here for quick access.

Hanwha SolarOne Co., L.Ş. Message Board

doc.science13000 8 posts  |  Last Activity: Jun 12, 2015 7:03 AM Member since: Dec 18, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • doc.science13000 by doc.science13000 Jun 12, 2015 7:03 AM Flag

    Does anyone have the information for the law firm handling the shareholder lawsuit? I signed up, but somehow lost there info and wanted to check on the status on that. I would think its been about 18 months since it was filed.

    Sentiment: Strong Sell

  • doc.science13000 by doc.science13000 May 29, 2015 2:52 AM Flag

    Opexa CEO Warma also discussed a personalized T-cell immunotherapy platform for autoimmune disease. The therapy is custom tailored to patients; hopefully making it an effective way to treat the disease. They also talked about a company owned and scalable eGMP manufacturing facility, and the fact that OPXA now holds 98 domestic patents.

    Validation – Finally, Warma discussed validation the company has received validation with regard to Tcelna for SPMS through a potential partnership with Merck Serono and the fact that the company has received FDA Fast Track Designation for the approval of the treatment.

    Sentiment: Strong Buy

  • doc.science13000 by doc.science13000 May 29, 2015 2:48 AM Flag

    When it comes to the company’s pipeline, there was a big announcement made today. First off, Tcelna, the company’s prime candidate not only has very limited competition, but is currently in Phase 2b for secondary progressive multiple sclerosis (SPMS) and has an overall market potential around $7 billion. The company also announced an addition to their pipeline known as OPX-212; which they hope will prove to be an effective treatment for neuromyelitis optica, an ailment with no approved therapies at the moment. That makes OPX-212 the first treatment in the Opexa Therapeutics pipeline on the orphan indication side of the fence.

    Sentiment: Strong Buy

  • doc.science13000 doc.science13000 May 19, 2015 9:21 AM Flag

    Exactly,there is a 99% chance GS already has there position. Thats why the stock fell the day after earnings as they shorted it and then got in around $2.75-$2.80. Now the stock is back at $3 where it was at during earnings and by the time the public knows about GS position it will be at $5-$6. Thats when all these message board individual traders will buy in. The only way to win on Wall St is to buy low now and sell high later on the news. Not the other way around.

    Sentiment: Strong Buy

  • Reply to

    GS Analyst very impressed with BIOC.

    by doc.science13000 May 12, 2015 11:25 PM
    doc.science13000 doc.science13000 May 13, 2015 10:11 AM Flag

    I see them licensing their products overseas and getting a licensing fee plus royalties while continuing to develop new liquid exams. Since they have a few patents they could also be brought out by a bigger biotech. They have $19 million in cash and there market cap is only around $54 million. Thats only valuing there business at $34 million when liquid biopsy market is potentially worth billions. The next pr should take us to $5-6 range.

    Sentiment: Strong Buy

  • Reply to

    GS Analyst very impressed with BIOC.

    by doc.science13000 May 12, 2015 11:25 PM
    doc.science13000 doc.science13000 May 13, 2015 7:40 AM Flag

    He asked some very important questions about IP, overseas expansion and expanding there sales to managed healthcare. Obviously, the guy could have been a foreigner with slight accent but anyway that doesn't matter. What matters is that BIOC is heading in the right direction and pps will soon follow.

    Sentiment: Buy

  • doc.science13000 by doc.science13000 May 12, 2015 11:25 PM Flag

    During the CC yesterday the analyst from GS seemded to be very impressed with the CEO' s response to his questions. Im sure they will open a position soon if not already. By the time the public knows GS and other hedgefunds have brought large positions they will be buying those shares back at $10 and above. Thats how it works in the market. I was impressed as well and look forward to the company's next achievements.

    Sentiment: Strong Buy

  • doc.science13000 by doc.science13000 May 6, 2015 7:10 AM Flag

    Has a nice pipe line of products, but could use the help from a major pharmaceutical company that has greater scale and deeper pockets. Also, currently working with only one POP network provider that has 19 million subscribers so they have plenty of room to grow here. Will be interesting to see the new institutional investors next week after the CC. Looking to pop over $5 soon.

    Sentiment: Buy

HSOL
0.00(0.00%)